SCHEMBL7093398

SCHEMBL7093398

CC1Oc2ccc(CC(C)N(Cc3ccccc3)C(=O)OC(C)(C)C)cc2NC1=S

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 3/20 0.41
HSD17B10 Q99714 4/20 0.35
ALOX15 P16050 2/20 0.35
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
ABCB1 P08183 3/20 0.33
POLB P06746 2/20 0.32
TSHR P16473 1/20 0.32
ALDH1A1 P00352 2/20 0.31
MAPK1 P28482 2/20 0.31
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
AKT1 P31749 2/20 0.31
L3MBTL1 Q9Y468 2/20 0.31
LMNA P02545 1/20 0.31
TRPM8 Q7Z2W7 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710846 0.90 PARP1 (0.53) PARP1HSD17B10ALOX15ALDH1A1MAPK1
SCHEMBL7710837 0.86 PARP1 (0.40) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL7704945 0.85 HDAC3 (0.44) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL7088859 0.84 PARP1 (0.37) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL6309617 0.84 HDAC1 (0.43) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL6995053 0.80 POLB (0.34) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL7704961 0.79 HDAC3 (0.33) HSD17B10HDAC3HDAC1HDAC2NCOR2
SCHEMBL5472790 0.78 PARP1 (0.36) PARP1HSD17B10HDAC3HDAC1HDAC2
SCHEMBL7704907 0.78 HSD17B10 (0.38) PARP1HSD17B10ALOX15HDAC3HDAC1
SCHEMBL6304956 0.78 BRD4 (0.41) PARP1HSD17B10HDAC3HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1015437-B1 BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND THEIR USE IN PHARMACEUTICALS SCHERING AG (DE) 2003-12-03 EP disclosed
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed